13
BioTech Stock Report, April 2002
Bio Portfolio
We at BioTech Stock Report believe that science and technology are the key to the future. Achieving scientific advancements in t echnology
will fuel the growth of the biotechnology industry, making possible the creation of new drugs or therapeutics. We believe our picks are well posi-
tioned to take advantage of the technological advances that will improve the quality of human life.
Investors should recognize that this is a long-term portfolio, share price will fluctuate according to market conditions.
Company
Reference
Date Price
3-22
Price
%
1-mo
%
YTD
%
Inception
Institutional
% Ownership:
change +/-
Aggressive Growth
Abgenix (ABGX)
12-30-99 33.06
20.74
14.90
-36.81
-32.27
82:+2
ABGX has a full pipeline and plenty of collaborations agreement. With that in mind, we maintain, a buy below $25 with target price of $45.
Affymetrix (AFFX)
5-31-00 59.38
27.96
13.36
-25.40
-52.91
66:NC
AFFX is the leader in the maker of gene chips. The company expects product revenue to grow 25% to $245 in 2002 with profit betwe en $3 to $5
million. Continue to rate as a buy on the pull back.
Celgene (CELG)
4-28-00 47.06
25.70
-1.49
-20.63
-45.39
64:+1
The company has decided to hold an additional trial for Thalomid for multiple myeloma. We maintain our buy below $25.
Cell Genesys (CEGE)
3-27-97 6.25
17.11
13.61
-25.35
173.76
61:NC
Transkaryotic Therapies (TKTX) reached a settlement on gene therapy patent interferences involving Novartis AG's (NVS) Genetic T herapy Inc.
unit, Roche Holding AG's (RHHBY) Syntex and Cell Genesys. Buy below $18.
Ciphergen (CIPH)
3-30-01 4.44
6.56
13.49
-16.86
47.75
41:NC
CIPH and Beckman form an alliance to automate clinical proteomics using CIPH's biomarker and assay proteomic chips combined with Beckman's
processors. CIPH share price appears to have a resistant level of $7, buy on weakness.
Dendreon Corporation (DNDN) 10-31-00 16.38
5.02
54.46
-48.78
-69.35
38:NC
DNDN reported 4th qtr and year-end EPS of a loss of 37 cents and 94 cents respectively. DNDN release mixed preliminary interim Phase III results
for Provenge to treat prostate cancer earlier this year. Company to release full data in mid-2002. Thus, watch and see.
Genzyme Biosurgery (GZBX)
12-29-00 8.69
6.20
-.80
15.89
-30.65
38:+1
GZBX is expect to reach profitability by the second half of this year. Buy below at $6.
ICOS (ICOS)
6-30-98 18.00
51.13
19.18
-9.42
184.06
58:NC
Cialis' NDA was submitted on 6-28-01 and ICOS is awaiting FDA response by mid-year. Eli Lilly, ICOS' partner for Cialis is having some manufac-
turing problems with "other" drugs that may effect the timing approval for Cialis. Nevertheless, ICOS' share price has had a nice run the past
month, change from buy below $40 to hold based upon valuation.
